You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科兴疫苗有效率达50%门槛 惟再要求巴西推迟公布详细测试数据
阿思达克 12-24 08:22
《路透社》报道,根据巴西布坦坦研究所(Butantan Institute)发表的第三期临床测试数据显示,科兴生物(SVA.US)新冠疫苗的有效率为50%以上,科兴生物已要求推迟15日才公布大效率的精确数据,以便整合来自全球的不同数据。

今次已是科兴生物第三次要求推选公布数据,相信这将加剧外界对中国疫苗生产商缺乏透明度的批评。巴西总统博索纳罗此前已多次对中国的疫苗提出质疑,而本月初巴西一项民意调查显示,有一半巴西人拒绝接种疫苗。

巴西卫生监督局(Anvisa)已将流行疫苗的有效率为至少50%,意味着科兴生物的新冠疫苗已经可以在巴西紧急使用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account